These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27789571)

  • 1. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.
    Landmesser U; Chapman MJ; Farnier M; Gencer B; Gielen S; Hovingh GK; Lüscher TF; Sinning D; Tokgözoglu L; Wiklund O; Zamorano JL; Pinto FJ; Catapano AL; ;
    Eur Heart J; 2017 Aug; 38(29):2245-2255. PubMed ID: 27789571
    [No Abstract]   [Full Text] [Related]  

  • 2. The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia.
    Pokharel Y; Virani SS; Ballantyne CM
    Curr Atheroscler Rep; 2015 May; 17(5):508. PubMed ID: 25782778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
    Gencer B; Koskinas KC; Räber L; Karagiannis A; Nanchen D; Auer R; Carballo D; Carballo S; Klingenberg R; Heg D; Matter CM; Lüscher TF; Rodondi N; Mach F; Windecker S
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein convertase subtilisin/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications.
    Cokkinos DV; Cokkinos P; Kolovou G
    Arch Cardiovasc Dis; 2019; 112(8-9):455-458. PubMed ID: 31495741
    [No Abstract]   [Full Text] [Related]  

  • 5. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.
    Landmesser U; Chapman MJ; Stock JK; Amarenco P; Belch JJF; Borén J; Farnier M; Ference BA; Gielen S; Graham I; Grobbee DE; Hovingh GK; Lüscher TF; Piepoli MF; Ray KK; Stroes ES; Wiklund O; Windecker S; Zamorano JL; Pinto F; Tokgözoglu L; Bax JJ; Catapano AL
    Eur Heart J; 2018 Apr; 39(14):1131-1143. PubMed ID: 29045644
    [No Abstract]   [Full Text] [Related]  

  • 6. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
    Ortega Martínez de Victoria E
    Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
    [No Abstract]   [Full Text] [Related]  

  • 7. CardioPulse: The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors.
    Blind E; de Graeff PA; Meurs I; Holtkamp F; Baczynska A; Janssen H
    Eur Heart J; 2016 Feb; 37(6):502-3. PubMed ID: 26853264
    [No Abstract]   [Full Text] [Related]  

  • 8. Statement for Appropriate Clinical Use of PCSK9 Inhibitors.
    Nohara A; Ohmura H; Okazaki H; Ogura M; Kitagawa K; Koseki M; Sato K; Tsukamoto K; Yamashita S;
    J Atheroscler Thromb; 2018 Aug; 25(8):747-750. PubMed ID: 29899173
    [No Abstract]   [Full Text] [Related]  

  • 9. New concepts in the management of dyslipidaemiaa.
    Gencer B; Rodondi N; Mach F
    Swiss Med Wkly; 2016; 146():w14378. PubMed ID: 27878791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Up to date lipid lowering treatment].
    Paragh G; Karádi I
    Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience.
    Saeed A; Virani SS; Jones PH; Nambi V; Zoch D; Ballantyne CM
    J Clin Lipidol; 2017; 11(3):596-599. PubMed ID: 28506382
    [No Abstract]   [Full Text] [Related]  

  • 12. [PCSK-9 inhibitors, effects on LDL-C and future implications: What you should know].
    Corral P; Ruiz AJ
    Hipertens Riesgo Vasc; 2017; 34(4):176-183. PubMed ID: 28709786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A short review of proprotein convertase subtilisin/kexin type 9 inhibitors.
    Alali RA
    Rev Cardiovasc Med; 2019 Mar; 20(1):1-8. PubMed ID: 31184090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
    Pirillo A; Catapano AL
    Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor.
    Shapiro MD; Miles J; Tavori H; Fazio S
    Ann Intern Med; 2018 Mar; 168(5):376-379. PubMed ID: 29181527
    [No Abstract]   [Full Text] [Related]  

  • 16. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk assessement and its management: from SCORE to statins, ezetimibe to PCSK inhibitors.
    Lüscher TF
    Eur Heart J; 2017 Aug; 38(29):2233-2236. PubMed ID: 28810720
    [No Abstract]   [Full Text] [Related]  

  • 18. [Recommendations of the European Society of Cardiology and the European Atherosclerosis Society on Cardiovascular Disease Prevention and Management of Dyslipidemias. for the Diagnosis of Atherosclerosis and Dyslipidemia Treatment (2016): Basic S.G.].
    Bubnova MG; Kukharchuk VV
    Kardiologiia; 2017 Mar; 57(3):85-89. PubMed ID: 28762942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
    Sabatel-Pérez F; García-Ropero A; Santos-Gallego CG; Urooj Zafar M; Badimón JJ
    Drugs Today (Barc); 2019 May; 55(5):329-344. PubMed ID: 31131843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function.
    Amput P; McSweeney C; Palee S; Phrommintikul A; Chattipakorn SC; Chattipakorn N
    Biomed Pharmacother; 2019 Jan; 109():1171-1180. PubMed ID: 30551367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.